Multiple endocrine adenomatosis (Type I) and familial hyperparathyroidism

R. T. Jung  
M.B., M.R.C.P.

M. Davie  
M.B., M.R.C.P.

A. M. Grant  
M.B., M.R.C.P.

D. Jenkins  
M.B., B.S.

T. M. Chalmers  
M.D., F.R.C.P.

Addenbrooke’s Hospital, Cambridge

Summary
Hyperparathyroidism is the commonest presenting feature in multiple endocrine adenomatosis Type I (MEA Type I), the other manifestations may be delayed for many years or appear only in relatives. A family now diagnosed as MEA Type I, who was previously thought, in 1965, to have familial hyperparathyroidism due to chief cell hyperplasia is now described. The importance is stressed of family surveillance and long-term follow-up in all cases of primary hyperparathyroidism. Those tests that are essential in the long-term surveillance of the patients and their first degree relatives are discussed.

Introduction
In recent years there has been increasing awareness of the multiple endocrine adenomatosis (MEA) syndromes. In MEA Type I there is a grouping of tumours or hyperplasia of the parathyroids, pancreatic islets and pituitary, while MEA Type II is characterized by phaeochromocytoma, medullary thyroid carcinoma and parathyroid pathology. In MEA Type I hyperparathyroidism is the commonest presenting feature and other manifestations may be delayed for many years or appear only in relatives. The importance of long-term family surveillance is illustrated by the following case study which brings up to date the story of a family previously reported as an example of familial primary hyperparathyroidism due to chief cell hyperplasia (Adams et al., 1965; Peters et al., 1966).

Case report
A 40-year-old housewife (II, in Table 1) was admitted in April 1976 with acute myelo-monocytic leukaemia. Between 1960 and 1963 exploration of the neck had been performed on four occasions for chief cell hyperplasia. Hypocalcaemia developed after the last of these operations and serum calcium concentration was subsequently maintained within normal limits with two tablets of calcium and vitamin D BPC (1000 i.u.) per day. Between 1950 and 1954 she had had recurrent peptic ulceration. Studies in 1963 revealed no radiological evidence of peptic ulcer but steatorrhoea was present. In 1974 faecal fat excretion was 30 g/day. A pentagastrin test showed only mild hyperacidity. Fiberscopy showed normal antral mucosa: jejunal biopsy was unsuccessful. Barium studies showed no abnormality in the stomach or duodenum: there was dilatation of the small bowel with contrast flocculation. After a gluten-free diet for one year faecal fat excretion was unchanged.

Until acute leukaemia developed in 1976 the patient remained clinically well. By then, serum gastrin estimation was available and the concentration was found to be > 120 pmol/l (normal range, < 50 pmol/l). Serum calcitonin was 3.8 μg/l (normal range, < 0.1 μg/l). The pituitary fossa was of normal size. Plasma cortisol concentrations and urinary excretion of 5-HIAA and HMMA were normal. Serum thyroxine was 46 nmol/l (normal range, 55–144 nmol/l). Remission of the leukaemia was not achieved with chemotherapy and she died in May 1976.

At post-mortem there was one remaining parathyroid gland which showed chief cell hyperplasia. There was a small diffuse pituitary adenoma and a thyroid colloid cyst with no evidence of a medullary thyroid carcinoma. Five benign ulcers were present in the duodenum. Islet cell tumours were found in the pancreas, in one adjacent lymph node and at two sites in the first part of the duodenum. The adrenal glands were normal. Leukaemic granulocytic proliferation was present in the spleen, bone-marrow and bowel wall.
Multiple endocrine adenomatosis and hyperparathyroidism

Family study

The family tree is shown in Table 1. Female patients II, II, and III have undergone parathyroidectomy for chief cell hyperplasia. On confirmation that II had MEA Type I a systemic biochemical survey of the family was carried out, including serum gastrin, calcitonin, parathyroid hormone, prolactin and thyroxine, fasting serum calcium, phosphate, glucose and insulin and urinary HMMA and 5-HIAA. The only new abnormality found was in patient III whose serum calcium was 2.7 mmol/l (10.8 mg/100 ml), albumin 46 g/l, phosphate 0.99 mmol/l (3.06 mg/100 ml), parathyroid hormone 2 ng/ml (normal range, < 0.9 mg/ml) and calcitonin 0.32 μg/l (normal range, < 0.1 μg/l).

Discussion

MEA Type I is inherited through an autosomal dominant gene with incomplete penetrance, and endocrine dysfunction can be variable with single or multiple involvement in any one family and at any age. The most frequent presenting feature is hypercalcaemia. In a recent series of 119 cases of primary hyperparathyroidism evidence of MEA was found in 17.5% and in 43% where two or more parathyroid glands were hyperplastic or adenomatous (Boey et al., 1975). In another series MEA was present in 18% of cases with chief cell hyperplasia (Castleman, Schantz and Roth, 1976).

In a recent study of the relatives of 100 consecutive patients with tumours or hyperplasia of the parathyroids, involvement of at least one additional family member was observed in ten index cases in the 91 of whom family data could be obtained (11%). MEA Type I was found in three families and MEA Type II in two families (Jackson, Frome and Block, 1977).

Cases with features of both MEA Type I and Type II have been reported recently (Hansen et al., 1976). Patient II in the present series showed a raised calcitonin (3.8 μg/l) but as no medullary thyroid carcinoma was found this was probably secondary to the raised gastrin (Sizemore et al., 1973). The patient's nephew, III, also had a slightly raised calcitonin (0.32 μg/l) with a raised serum parathyroid hormone and calcium but normal gastrin. A pentagastrin–calcitonin stimulation test did not suggest medullary thyroid carcinoma, and the raised calcitonin might have been due to the raised calcium or parathyroid hormone (Sizemore and Go, 1975; Tashjian et al., 1970).

This case study emphasizes the importance of family surveillance and long-term follow-up in primary hyperparathyroidism. The authors suggest that all first degree relatives of patients with primary hyperparathyroidism, particularly when it is due to chief cell hyperplasia, should have a full clinical assessment and serum calcium and phosphate estimations. Further follow-up may be necessary in

Table 1. Pedigree. Affected members of the family are shown as solid symbols, their age in years is given in parentheses

<table>
<thead>
<tr>
<th>I</th>
<th>1♂</th>
<th>2♀ (deceased)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(73)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>II</th>
<th>1♀</th>
<th>2♀</th>
<th>3♀</th>
<th>4♀</th>
<th>5♀</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(48)</td>
<td>(44)</td>
<td>(40)</td>
<td>(40)</td>
<td>(38)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>III</th>
<th>1♀</th>
<th>2♀</th>
<th>3♀</th>
<th>4♀</th>
<th>5♀</th>
<th>6♀</th>
<th>7♀</th>
<th>8♀</th>
<th>9♀</th>
<th>10♀</th>
<th>11♀</th>
</tr>
</thead>
</table>
families particularly where the initial studies reveal involvement of more than one member. The cost of detailed endocrine studies, such as those reported in this article, at present precludes their use except where there are definite clinical indications.

Acknowledgments
We thank the Regional Hormone Assay Service of Addenbrooke's Hospital and the Supraregional Assay Service of Hammersmith Hospital (especially Dr Carole Hillyard) for the provision of the hormone assays.

References
Multiple endocrine adenomatosis (Type I) and familial hyperparathyroidism.

R. T. Jung, A. M. Grant, M. Davie, D. Jenkins and T. M. Chalmers

doi: 10.1136/pgmj.54.628.92

Updated information and services can be found at:
http://pmj.bmj.com/content/54/628/92

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/